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 1 
Abstract 2 
 3 
Background: 4 
 5 
Studies have reported that pharmacologic interventions with candesartan or ramipril could 6 
reduce the risk of hypertension among prehypertensive subjects free of clinical 7 
cardiovascular disease(CVD), however, the cost-effectiveness and long-term cardiovascular 8 
risk of drug treatment among these population is unclear.   9 
Method:  10 
A Markov state-transition model was developed to simulate a hypothetical cohort of Chinese 11 
adults with high-range prehypertension (130-139/85-89 mmHg) but without CVD. Data on 12 
the incidence of CVD and hypertension was obtained from corresponding risk equations. 13 
Utility and disease-related costs were obtained from published literatures. Robustness and 14 
uncertainty was evaluated using deterministic and probabilistic sensitivity analyses. 15 
Results:  16 
Compared with placebo, drug treatment resulted in delaying the development of hypertension 17 
by nearly 12 years and reducing the absolute incidence of hypertension by 32.01% over 18 
lifetime. The cumulative incidence of coronary heart disease, stroke and heart failure were 19 
reduced and survival was improved from 28.46 to 28.80 years. The average incremental cost 20 
effectiveness ratio for drug treatment was $12,994 per quality-adjusted life-year and the value 21 
was mostly sensitive to the effect size of treatment and age starting treatment. At a 22 
willingness-to-pay threshold of >3×China gross domestic product per capita in 2014, there 23 
was a 30.48% chance that drug treatment would remain cost-effective and a low chance of 24 
being cost-effective if relative risk of treatment on hypertension was larger than 0.64. 25 
Conclusion: Drug treatment for prehypertension may help stem the current epidemic of 26 
hypertension among Chinese adults free of CVD, which may in turn reduce CVD 27 
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complications and potentially be cost effective. 1 
1. Introduction 2 
 3 
Hypertension is the leading risk factor for cardiovascular disease (CVD) in China and it 4 
contributes to 2.33 million cardiovascular deaths in 2005[1]. Despite tremendous efforts to 5 
promote healthful lifestyles and drug treatment rate, the prevalence of hypertension has 6 
increased from 20% among men and 17% among women in 2002 to 31.2% and 28.0%, 7 
respectively, in 2009[2, 3]. The term of “prehypertension” was introduced in Seventh Report 8 
of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High 9 
Blood Pressure (JNC-VII) to highlight an at-risk population. It is believed that 10 
prehypertension is a precursor of clinical hypertension and successfully control this 11 
population would reduce the potential cardiovascular burden [4].  12 
Currently, the treatment of prehypertension is primarily nonpharmacological lifestyle changes 13 
such as healthy dietary habits, overweight/obesity control [5]. However, an important 14 
obstacle to the success of these strategies is that lifestyle modification treatments are difficult 15 
to maintain and may require large-scale social and policy changes as well as the patients 16 
himself [5]. The trial of preventing hypertension(TROPHY) study was the first trial to 17 
perform pharmacological intervention amongst individuals with prehypertension. Results 18 
from TROPHY suggested that treatment with Candesartan significantly reduced the incidence 19 
of hypertension, even after discontinuing drug therapy for 2 years [6]. This is in agreement 20 
with another clinical trial (prevention of hypertension with the angiotensin-converting 21 
enzyme inhibitor ramipril in patients with high-normal blood pressure(PHARAO) study) 22 
performed in Germany [7]. In this study, Ramipril is proved to be effective in reducing the 23 
incidence of office hypertension by 34.4%. However, there are no studies to assess whether 24 
early drug treatment of prehypertension can reduce its long-term cardiovascular 25 
consequences. 26 
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Additionally, nearly 30% of the general adult population in China have prehypertension and 1 
the health and economic consequences caused by prehypertension are substantial [8-10]. It is 2 
important that an effective strategy must be carefully chosen on the basis of both public 3 
health and economic reasons. However, we are still unclear whether prescribing drugs among 4 
individuals with prehypertension but without clinical CVD is cost-effective, given the 5 
relatively low absolute risk amongst this population [11, 12]. 6 
The aim of our study was to combine data from published clinical trials and epidemiological 7 
studies to predict 1) medium and long-term hypertension incidence and its associated 8 
cardiovascular risk and 2) the lifetime cost-effectiveness of pharmacological therapy versus 9 
placebo intervention among individuals with prehypertension free of CVD. 10 
2. Method 11 
2.1 Model structure  12 
We adopted a similar approach to develop a state-transition Markov model used by Herman 13 
et al for the primary prevention of type 2 diabetes mellitus in adults with impaired glucose 14 
tolerance [13]. Our model simulated the progression from prehypertension to onset of 15 
hypertension, to hypertension with complications and death. Simultaneously, this model 16 
allowed individuals with prehypertension to move to CVD/death directly (Figure 1). In total, 17 
we modelled the following 10 distinct health states: (1) healthy with prehypertension; (2) 18 
hypertension; (3) stroke; (4) post stroke; (5) coronary heart disease(CHD); (6) post CHD; (7) 19 
heart failure (HF); (8) post HF; (9) CVD mortality and (10) non-CVD mortality. After each 20 
cycle, cohort members were redistributed to one of the above ten health states. Individuals 21 
reaching a CVD state by the end of the first year could subsequently transit to another state 22 
(e.g., the occurrence of stroke after HF). Subsequent to a primary event, patients might move 23 
to a chronic heath state (post CHD or post HF or post stroke), which had a higher risk to 24 
suffer a new CVD event or death. Due to the lack of data, some states were not modelled (e.g., 25 
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myocardial infarction after post-stroke). Subjects transiting to hypertension had a similar 1 
pathway as those with prehypertension, but they could not return to prehypertension (linear 2 
model without remission) and had a different pre-specified transition probability. The detailed 3 
transition pathways could be found in the online supplementary Figure A1 to Figure A5. 4 
In this study, we simulated two cohorts: one that followed individuals who received placebo 5 
treatment (placebo intervention) and the other one which followed individuals who were 6 
prescribed antihypertensive treatment (drug treatment).  This will keep consistence with the 7 
two completed trials[6-7] after considering the fact that no head-to-head clinical trials were 8 
performed to compare drug treatment, intensive lifestyle changes and usual care. All 9 
prehypertensive individuals entered the model with their pre-specified characteristics and 10 
were followed along the disease paths until they turned 100 years old or died. The model 11 
cycle length was 1 year, and half-corrections were applied. A more detailed description for 12 
the base-case study population could be found in the online supplementary file. 13 
2.2 Transition probability  14 
The values for the transition probabilities and other inputs were mainly obtained from 15 
published evidences among Chinese population and summarized in Table 1. A prediction 16 
model for hypertension risk was used for estimating hypertension incidence rate [14]. The 17 
incidence of each primary CVD events (stroke, HF and CHD) was derived from their 18 
corresponding risk equations reported in studies [15-17] on the basis of individual data from 19 
Nanjing Community Cardiovascular Risk Survey study [18]. This will keep the correlation 20 
between each of the risk factors. The distribution for each risk factors among participants 21 
with prehypertension and hypertension could be found in online supplementary Table A3 22 
and Table A4. As the age in this study was mainly from 30 to 75 years old, exponential 23 
interpolation was employed to smooth the age-specific annual rates to persons older than 75 24 
years (online supplementary Figure A6 and A7). A detailed description for the estimation of 25 
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primary CVD event rate could be found in the online supplementary file.  1 
Each primary event might be followed by secondary events or chronic conditions, and 2 
individual who experienced a first non-fatal cardiovascular event would have a higher risk of 3 
sequelaes. As there were no suitable risk equations to calculate the risk for each age/sex 4 
stratum among Chinese population, transition probabilities for subsequent events (within or 5 
more than 1 year after a primary event) were drawn from registries and/or meta-analysis 6 
studies [19-24]. These rates were varied in sensitivity analyses (online supplementary Table 7 
A5). However, for the sake of conservative estimation, the probabilities of new events in any 8 
of the post-CVD states were not adjusted their different blood pressure (BP) categories.  9 
As evidences in the published literature demonstrated that prehypertension may be associated 10 
with higher CVD mortality, we separated mortality into CVD and non-CVD mortality [1, 8]. 11 
Age- and sex-specific risks of all-cause/CVD mortality were derived from Chinese National 12 
Statistical Office in 2013[25]. The non-CVD mortality risks were recalculated after exclusion 13 
of CVD death from the total mortality and this was assumed to be unaffected by the states in 14 
the model.  15 
2.3 Treatment effect  16 
Antihypertensive treatment could significantly decrease the risk of CVD morbidity or 17 
mortality by lowering BP among patients with hypertension as well as those with clinical 18 
history of CVD but without hypertension [26-28]. However, trials to date could only indicate 19 
a deceasing risk of incident hypertension, rather than a reduction in CVD risk among 20 
prehypertensive individuals without prior CVD [6, 7, 11]. Our model only incorporated the 21 
benefits of drug treatment in hypertension incidence, and made the conservative assumption 22 
of no effect in CVD risk (Table 1).  23 
2.4 Cost  24 
Costs data were obtained from multiple sources, including the China Health Statistics 25 
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Yearbook report and health economics researches (Table 1). For costs of prehypertension, we 1 
assumed it was the same as those with hypertension, although the dose for this specific 2 
population may be lower. This approach could be justifiable because it would lead to a 3 
conservative estimate. In our model, we used the data from a cost-effectiveness and an 4 
observational study [29, 30]. For costs of CVD events during year 1, the values were obtained 5 
from several recently published articles which included detailed breakdown costs (eg, drug 6 
cost, salary costs of primary healthcare providers) [31-34]. Cost of recurrent stroke or MI 7 
were captured by applying the same cost of first-year events. The costs were estimated from a 8 
health system perspective and were inflated to the 2014 price level using the average rate of 9 
inflation in China from 2009 to 2014 and converted to US dollars (6.25 Yuan≈1 USD 2014). 10 
A more detailed description for cost estimation could be found in the online supplementary 11 
file. 12 
2.5 Utility  13 
The utility measured in a 2008 survey in China was applied to individuals without CVD [35]. 14 
We derived utility weight of CHD, stroke or HF from a published cost-effectiveness study 15 
[36], as the preference weights for them were not available in Chinese population (Table 1). 16 
Quality-adjusted life-years (QALYs) were calculated by multiplying the length of time spent 17 
in a certain health state by the utility associated with that health state.  18 
2.6 Base-case analysis  19 
We used results from the Nanjing Community Cardiovascular Risk Survey study as a proxy 20 
for participants with prehypertension [18]. On average, members of the cohort had a mean 21 
age of 50.5 years, were 54.4% female, had a mean systolic blood pressure(SBP), diastolic 22 
blood pressure(DBP) and body mass index(BMI) of 131.9mmHg, 82.4 mmHg, 24.5 kg/m2 , 23 
respectively. Using our base-case cohort, we assessed the simulated 5-year, 10-year and 24 
lifetime cumulative incidence of hypertension, CVD events and life expectancy by the 25 
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method of Markov model cohort simulation. Incremental cost-effectiveness ratios (ICERs) 1 
were also calculated by dividing the incremental change in total healthcare costs by the 2 
incremental change in QALYs. The degree of cost-effectiveness was evaluated based on the 3 
WHO Choosing Interventions That Are Cost Effective (highly cost-effective, ICER less than 4 
the gross domestic product(GDP) per capita; moderately cost-effective, ICER of 1-3×GDP 5 
per capita; and not cost-effective, ICER of>3×GDP per capita) [37]. The gross domestic 6 
product(GDP) per capita of China in 2014 was reported to be $7,593.9 from the World Bank 7 
report [38]. Cost and utility would be both discounted at a 3% annual rate in the future for the 8 
primary projections. All analyses were conducted using a life-time horizon unless otherwise 9 
indicated. 10 
2.7 Analysis of uncertainty 11 
The impact of uncertainty in model variables on the ICER was tested by a series of sensitivity 12 
analyses. First, in the 1-way sensitivity analysis, each input parameter was varied over a set 13 
of plausible ranges provided in Table 1 and online supplementary Table A5. Second, a two-14 
way sensitivity analysis was performed to assess how large the changes of the first two key 15 
inputs must be in order to exceed the cost-effective threshold (ICER of >3×GDP per 16 
capita=$22,782). Third, in order to assess how sensitive the results were to variations in 17 
simultaneous changes of several variables, we also conducted a probabilistic sensitivity 18 
analysis (PSA). We ran our model for 5,000 repetitions using a Monte Carlo simulation and at 19 
each simulation a value for each of the 54 model parameters were randomly selected based 20 
on their respective distributions, which were shown in Tables 1 and online supplementary 21 
Table A5. In our model, probabilities, prevalence rates, and preference weights were assumed 22 
to follow a beta distribution, and cost data were assumed to follow a gamma distribution. 23 
Additionally, uniform and triangular distributions were used where appropriate. The 24 
incremental cost-effectiveness scatter plot and acceptability curve were constructed to test the 25 
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uncertainty of ICER from the derived 5,000 pairs of incremental cost and QALYs between 1 
these two strategies. 2 
3 
11 
 
 1 
3. Results  2 
3.1 Model validation  3 
The findings from our model indicated a reasonable concordance between model predictions 4 
and national life tables (30.20 vs. 31.31 for women, 26.69 vs. 27.21 for men). Our results 5 
showed that the 5-year absolute cardiovascular risk (except HF) was relatively low (2.58%), 6 
however, each event rate was found to be within reported ranges (online supplementary 7 
Tables A6). 8 
3.2 Base-case analysis  9 
Using baseline estimates, our model simulated the lifetime cumulative incidence of 10 
hypertension, which was shown in online supplementary Tables A8. The figure indicated 11 
that approximately 30% of individuals with placebo would develop hypertension within 5 12 
years, however, it would take more than 17 years to achieve that percent for those prescribed 13 
antihypertensive medication. Thus, compared to placebo, the drug intervention delayed the 14 
onset of hypertension by about 12 years. Over a lifetime, prescribing drugs among 15 
individuals with prehypertension would reduce the risk for developing hypertension by 16 
32.01% (Table 2).  17 
Table 2 summarizes the potential changes in CVD events and life expectancy as well as costs, 18 
which may be caused by the delaying or reduction of hypertension risk. In general, risk 19 
reductions in CHD, stroke and HF were observed for all different time horizons. The 20 
reduction in mortality or clinical event risk from drug treatment increased life expectancy by 21 
0.34 years and QALYs by 0.22 (undiscounted: 0.09), whereas it increased discounted costs 22 
from $3,690.1 to $4,859.5 (an increment of $1,169.4). Therefore, based on the WHO criteria, 23 
the discounted lifetime ICERs might be moderately cost-effective ($12,994 per QALY within 24 
ICER of 1-3×GDP per capita). 25 
 26 
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 1 
3.3 Uncertainty analysis 2 
Our cost-effectiveness analysis was relatively insensitive to a variety of alternative 3 
assumptions (online supplementary Figure A9), specifically for those relating to secondary 4 
CVD events. The 10 individual parameters that were most influential in ICER estimates. 5 
were RR of hypertension on treatment, age starting treatment, BMI, drug treatment costs, 6 
discount rate, SBP, utility of stroke, incidence of stroke among hypertensive persons, utility 7 
of non-CVD state, and DBP.  8 
A two-way sensitivity analysis was performed to investigate the relationship of the two most 9 
influential variables (RR of hypertension on treatment and age starting treatment). At a 10 
willingness-to-pay threshold of $22,870 per additional QALY (3 times the GDP), our model 11 
indicated that the probability of being cost-effective increased with age and decreased with 12 
the higher RR of hypertension on treatment, but there was low probability if the RR of 13 
treatment was larger than 0.64 (online supplementary Figure A10). 14 
To further reflect the uncertainty in the estimates, the incremental cost-effectiveness scatter 15 
plot was derived from PSA (online supplementary Figure A11). In comparison with 16 
placebo, prescribing drug to participants with prehypertension would result in an increase in 17 
QALYs in 99.70% of simulations. Regarding the incremental costs, drug treatment for 18 
prehypertension would decrease costs in 5.87% of simulations. Overall, the cost-effectiveness 19 
for drug treatment was 30.48% with a maximum willingness to pay to be $22,870 per 20 
additional QALYs. Also, we found an increasing probability of being cost-effective if the 21 
decision maker was willing to pay more for an additional health gain, and a 5.80% of the 22 
probability that drug intervention was cost-saving (Figure 2).  23 
24 
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 1 
4. Discussion: 2 
This study provides evidence that drug treatment with the angiotensin-converting enzyme 3 
inhibitor ramipril or the angiotensin receptor antagonist candesartan for prehypertension, as 4 
compared with placebo intervention, could delay and/or prevent hypertension by 5 
approximately 12 years over a lifetime, which would result in a reduction in cardiovascular 6 
complications and an increase in life expectancy. In addition, when patients’ preferences and 7 
cost of treatment were both taken into account, we found that prescribing drugs among 8 
prehypertension was moderately cost-effective, costing $12,994 per QALY. 9 
In comparison with other currently accepted medical interventions for hypertension or CVD, 10 
our study found a relative smaller life-year or CVD gains from our base-case model [36, 39-11 
42]. For example, our models projected that an antihypertensive intervention would prolong 12 
life expectancy of prehypertensive individuals by 0.34 years. By contrast, Tsevat et al [39] 13 
predicted that BP control could increase gains in life expectancy of 2.3 and 1.7 years in men 14 
and women, respectively. Geisler et al [36] estimated that renal denervation substantially 15 
increased median survival from 17.1 years to 18.4 years and reduced cardiovascular mortality 16 
by 30% and all-cause mortality by 15%. We also found a comparable benefit showing 17 
metformin interventions could only improve survival by 0.2 years among drug therapy in 18 
adults with impaired glucose tolerance [13]. We believed that the relative smaller benefits in 19 
our study may be ascribed to the relatively low absolute risk of CVD for this specific 20 
population (prehypertension but without CVD) and assumption of no effect on CVD 21 
incidence by drug treatment.  22 
In general, the overall conclusions of the cost-effectiveness analysis for our study were robust 23 
to the ranges of uncertainty surrounding utility weights, and costs as well as treatment effect. 24 
Although it seemed that the judgment of cost-effectiveness was most sensitivity to the RR of 25 
antihypertensive treatment, it was still important that health policy should be based on what is 26 
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determined to be an acceptable ICER. The acceptable ICER from our relative low CVD risk 1 
population (2.58% of 5-year CVD risk) may support the concept of using predicted baseline 2 
CVD risk equations to guide blood pressure-lowering treatment decisions, not just the BP 3 
levels [26, 43, 44]. This is because prehypertensive subjects often exhibited several additional 4 
risk factors (e.g., dyslipidemia, obesity) and could have the same absolute CVD risk with 5 
those with hypertension [10, 12]. The idea of implementing intensive BP control in high-risk 6 
patients was confirmed by SPRINT trial, which may partly support our study results.   7 
Several limitations need to be acknowledged in our study. First, due to the lack of evidences 8 
to show the benefits on CVD risk by drug treatment among  prehypertensive subjects without 9 
CVD, our model only captured the benefit of hypertension risk and assumed no direct 10 
benefits on stroke, CHD, and HF. This limitation might underestimate the benefit and result 11 
in conservative estimates. Second, we did not incorporate the rate of drug side effects and 12 
their associated costs in our model, however, it is anticipated to have little influence on the 13 
final evaluation as both studies reported a comparable and low rate of serious adverse events 14 
between groups and no concerns were raised for adverse reactions caused by drug [6, 7]. 15 
Third, as there are no reports discussing the medication compliance of a life-long drug 16 
treatment among these healthy prehypertensive adults, a potential impact on our result may 17 
deserve more attentions. Fourth, many key inputs into the model were derived from Chinese 18 
population and we did not know whether our results were transferable to other countries, 19 
especially considering the large variations in costs from different countries. Finally, as all 20 
computer simulation studies, we were clear that average gains in life expectancy or ICER 21 
from the prediction models may not apply to the individual patient, and therefore results need 22 
to be interpreted with caution.  23 
In summary, our model projected that drug treatment in prehypertensive Chinese adults free 24 
of CVD could delay and/or prevent onset of hypertension and its complications. This policy 25 
15 
 
may be cost-effective and reasonable, but are highly dependent on the treatment effectiveness.  1 
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Figure titles and legends:  
Figure 1: Schematic Depiction of the Model 
              Hypertension module;              prehypertension module;                MI module;              HF module;             Stroke module 
Figure 2: Cost-effectiveness acceptability curve 
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Table 1 key model parameters 
AF: atrial fibrillation; BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; DM: diabetes mellitus; TC: total cholesterol; HDL: high-
density lipoprotein; FHS: family history stroke; HF: heart failure; LVH: left ventricular hypertrophy; CHD; coronary heart disease; RR: relative risk 
 
Data input  Base Case Numeric Value (Range) or Survival Model (Covariates) Distribution  Reference  
Age 50.5 (30-80)years Triangular [18] 
Sex 54.4(0-100)% female  Beta [18] 
BMI 24.5(20-30)kg/m2 Normal  [18] 
SBP 131.9(120-139)mmHg Triangular [18] 
DBP 82.4(65-89)mmHg Triangular [18] 
Hypertension incidence Weibull(age, sex, BMI, SBP, DBP) ±25% uniform [14] 
CHD incidence  Exponential (age, sex, DBP, SBP,TC, HDL, DM, Smoking)  ±25% uniform [16] 
Stroke incidence  Exponential (age, sex, DBP, SBP, FHS, AF, DM)  ±25% uniform [17] 
HF incidence Exponential (age, sex, SBP, DM, LVH, BMI, heart rate, CHD, valve disease) ±25% uniform [15] 
All-cause mortality Age and sex dependent  ±25% uniform [25] 
Stroke mortality First year: 12.3% for male, 17.8% for female; beyond: SMR 2.23(1.29–3.88) on background mortality Beta/ Lognormal [19-21] 
CHD mortality First year: 5.7%; beyond: SMR 1.43(1.18–1.72) on background mortality Beta/ Lognormal [20, 22] 
HF mortality First year: 15.9%; beyond: 8% Beta [23, 24] 
Effect of treatment  
 
  
RR of hypertension on treatment 0.34(0.25-0.95) Triangular [6, 7] 
Cost  
 
  
Annual cost for Antihypertensive treatment $161.44($53.76-$484.32) Gamma [29, 30] 
Annual cost for Stroke $3358.11($1,118.88-$10,074.24) first year, post $1,315.16($438.24-$3,945.44) Gamma [25, 31, 32] 
Annual cost for CHD $4,820.89($1,606.88-$14,462.56) first year, post $382.08($160.64-$1,446.24) Gamma [25, 33] 
Annual cost for HF $1,260.16($420-$3,780.48) first year, post $293.92($97.92-$881.76) Gamma  [25, 34] 
Quality of life weights(utilities) 
 
  
No cardiovascular disease Age and sex dependent  ±25% uniform [35] 
Stroke 0.63 (0.26 to 0.92) Beta [36] 
CHD First year: 0.76 (0.5 to 0.87); beyond: 0.88 (0.67 to 0.94) Beta [36] 
HF 0.71 (0.43 to 0.84) Beta [36] 
Discount rate 3% (0%-5%) Uniform Assumed  
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Table 2  Base-Case Results 
 
5-year time horizon  
 
10-year time horizon   
 
lifetime horizon  
Outcomes  
Placebo 
Intervention 
Drug 
Treatment RD RR   
Placebo 
Intervention 
Drug 
treatment RD RR   
Placebo 
Intervention 
Drug 
treatment RD RR 
Hypertension 31.37 11.80 19.57 0.38  
 
51.17 20.85 30.32 0.41  
 
80.66 48.65 32.01 0.60  
CHD,% 0.80 0.79 -0.01 0.99  
 
1.83 1.73 -0.10 0.95  
 
12.53 12.30 -0.23 0.98  
Stroke,% 1.46 1.42 -0.04 0.97  
 
3.49 3.21 -0.28 0.92  
 
26.89 25.41 -1.48 0.94  
HF,% 0.95 0.90 -0.05 0.95  
 
2.22 2.00 -0.22 0.90  
 
12.82 12.65 -0.17 0.99  
CV mortality,% 0.59 0.57 -0.02 0.97  
 
1.64 1.53 -0.11 0.93  
 
22.96 22.56 -0.40 0.98  
All-cause mortality,% 3.08 3.06 -0.02 0.99  
 
7.31 7.19 -0.12 0.98  
     Life years 
          
28.46 28.80 0.34 
 Undiscounted QALYs 
          
20.43 20.65 0.22 
 QALYs discounted,3% 
          
13.46 13.55 0.09 
 Cost discounted($),3% 
          
3690.1 4859.5 1169.4 
 Discounted ICER                     $12,994/QALY 
CHD; coronary heart disease; HF: Heart failure; QALYs: quality adjusted life years; ICER: incremental cost-effectiveness ratio; RD: risk difference; RR: relative risk  
 
